2015
Patient-Level Interventions to Prevent the Acquisition of Resistant Gram-Negative Bacteria in Critically Ill Patients: A Systematic Review
Zaky A, Zeliadt SB, Treggiari MM. Patient-Level Interventions to Prevent the Acquisition of Resistant Gram-Negative Bacteria in Critically Ill Patients: A Systematic Review. Anaesthesia And Intensive Care 2015, 43: 23-33. PMID: 25579286, DOI: 10.1177/0310057x1504300105.Peer-Reviewed Original ResearchConceptsPatient-level interventionsIntensive care unitMDR-GNBCare unitSystematic reviewMultidrug-resistant Gram-negative bacterial infectionsSelective digestive decontaminationComparative interventional studyGram-negative bacterial infectionsInfection control effortsResistant Gram-negative bacteriaRate of infectionPrevention of colonisationDigestive decontaminationInterventional trialsIll patientsInterventional studyAnalysed trialsControl groupBacterial infectionsInfectionInterventionTrialsSignificant reductionScience databases
2012
Targeting Brain Tissue Oxygenation in Traumatic Brain Injury
Martini RP, Deem S, Treggiari MM. Targeting Brain Tissue Oxygenation in Traumatic Brain Injury. Respiratory Care 2012, 58: 162-172. PMID: 23271826, DOI: 10.4187/respcare.01942.Peer-Reviewed Original ResearchConceptsBrain tissue oxygenationTraumatic brain injuryBrain injuryTissue oxygenationBrain tissue oxygenation monitoringManagement of patientsTissue oxygenation monitoringInvasive monitoring devicesPoor prognosisProspective studyRetrospective studyTherapy resultsPrognostic informationOxygenation monitoringOutcome differencesTherapeutic interventionsPhysiologic manipulationsOxygen challengeInjuryOxygenationAccepted practicePatientsPrognosisTherapyTrialsPseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial
Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal Of Cystic Fibrosis 2012, 12: 147-153. PMID: 22944725, PMCID: PMC3696392, DOI: 10.1016/j.jcf.2012.08.001.Peer-Reviewed Original ResearchConceptsPulmonary exacerbationsCF patientsP. aeruginosa eradicationP. aeruginosa isolationCystic fibrosis patientsEarly P. aeruginosaBaseline seropositivityEPIC trialPositive serologyAntibiotic therapyChild TrialTreatment failurePrognostic valuePseudomonas infectionWeek 10Fibrosis patientsSerologyCulture resultsPatientsClinicians' effortsExacerbationSeropositivityP. aeruginosaRiskTrials
2011
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
Mayer‐Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch‐Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, Investigators F. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology 2011, 47: 125-134. PMID: 21830317, PMCID: PMC3214247, DOI: 10.1002/ppul.21525.Peer-Reviewed Original ResearchConceptsExacerbation riskInitial eradicationCystic fibrosisPseudomonas aeruginosa acquisitionInitial antibiotic treatmentPositive respiratory culturesPA recurrenceProportional hazards modelSymptom-based definitionEPIC trialPulmonary exacerbationsAntibiotic therapyTreatment failureClinical benefitPA infectionRespiratory culturesSubsequent exacerbationAntibiotic treatmentEarly eradicationHigh riskNegative culturesExacerbationHazards modelSignificant predictorsTrials
2009
Which H is the most important in triple-H therapy for cerebral vasospasm?
Treggiari MM, Deem S. Which H is the most important in triple-H therapy for cerebral vasospasm? Current Opinion In Critical Care 2009, 15: 83-86. PMID: 19276798, DOI: 10.1097/mcc.0b013e32832922d1.Peer-Reviewed Original ResearchConceptsCerebral vasospasmSubarachnoid hemorrhageCirculatory volume expansionNew randomized trialsCerebral blood flowHemodynamic managementRandomized trialsHemodynamic variablesHypervolemic hemodilutionRegistry databaseBlood flowPaucity of informationVasospasmPhysiologic dataHemorrhagePhysiological studiesLow levelsHypertensionComplicationsHemodilutionTherapyRecent literatureTrials
2002
Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age?
Weiss NS, Treggiari MM. Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age? Obstetrics And Gynecology 2002, 100: 364-8. PMID: 12151165, DOI: 10.1016/s0029-7844(02)02046-x.Peer-Reviewed Original ResearchConceptsLong-term hormone useOlder postmenopausal womenPostmenopausal womenHormone useFracture riskYounger postmenopausal womenPostmenopausal hormone useSurrogate end pointsBone mineral densityUse of hormonesHormone therapySkeletal benefitsRandomized trialsSuch therapyMineral densitySkeletal fracturesAbsolute reductionEnd pointStudy of hormonesWomenHealth careTrialsAgeTrue declineRisk